ARTICLE | Company News
EMA to review Biofrontera's BF-200 ALA
September 30, 2010 12:56 AM UTC
The European Medicines Agency accepted for review an MAA from Biofrontera AG (Xetra:B8F) for BF-200 ALA to treat actinic keratosis. BF-200 ALA is a photodynamic therapy comprising nanoemulsion BF-200 ...